35 results on '"Wong, Stephane"'
Search Results
2. BCR/ABL Inhibition by an Escort/Phosphatase Fusion Protein
3. Modeling Philadelphia chromosome positive leukemias
4. Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system
5. Phosphoinositide 3-kinase signaling is essential for ABL oncogene–mediated transformation of B-lineage cells
6. Cell context–specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors
7. Abstract CT237: Evaluation of in vivo chimeric antigen receptor (CAR) transgene levels in patients (pts) treated with tisagenlecleucel
8. Abstract CT077: Potential utility of minimal residual disease (MRD) to identify relapse in pediatric and young adult (AYA) B-cell acute lymphoblastic leukemia (B-ALL) patients treated with tisagenlecleucel
9. Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene
10. Molecular Detection of Minimal Residual Disease Precedes Morphological Relapse and Could be Used to Identify Relapse in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia Patients Treated with Tisagenlecleucel
11. Evaluation of In Vivo CAR Transgene Levels in Relapsed/Refractory Pediatric and Young Adult ALL and Adult DLBCL Tisagenlecleucel-Treated Patients
12. Evaluation of In Vivo CAR Transgene Levels in Relapsed/Refractory Pediatric and Young Adult ALL and Adult DLBCL Tisagenlecleucel-Treated Patients
13. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase
14. Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study.
15. International Scale (IS)-Standardized BCR-ABL1 Digital Polymerase Chain Reaction (dPCR) Assays Using ABL1, BCR, and GUS Control Genes for Measuring Deep Molecular Response (MR) in Chronic Myeloid Leukemia (CML)
16. The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia
17. Analysis of Bcr-Abl Function Using an In Vitro Embryonic Stem Cell Differentiation System
18. Abstract 3491: Absolute quantification of EGFR activation and resistance mutations as well as copy number in circulating nucleic acids by droplet digital PCR.
19. Abstract 39: Clinical assessment of PTEN mutation in FFPE tissue: comparison of Sanger sequencing, immunohistochemistry and chromogenic in situ hybridization methods.
20. Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial
21. Next-Generation Sequencing of the BCR-ABL1 Kinase Domain and Neighboring Domains Associated with Therapy Resistance.
22. Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system
23. An MMR Control RNA for Reliable Monitoring of BCR-ABL Transcripts in Treated CML Patients.
24. The BCR-ABL Story: Bench to Bedside and Back
25. Analysis of Bcr-Abl Function Using an In Vitro Embryonic Stem Cell Differentiation System.
26. Regulation of the Oncogenic Activity of BCR-ABL by a Tightly Bound Substrate Protein RIN1
27. Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial
28. Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial
29. Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial
30. A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial
31. BCR/ABL inhibition by an escort/phosphatase fusion protein.
32. Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation
33. Phosphoinositide 3-kinase signaling is essential for ABLoncogene–mediated transformation of B-lineage cells
34. Cell context–specific effects of the BCR-ABLoncogene monitored in hematopoietic progenitors
35. International Scale (IS)-Standardized BCR-ABL1Digital Polymerase Chain Reaction (dPCR) Assays Using ABL1, BCR, and GUSControl Genes for Measuring Deep Molecular Response (MR) in Chronic Myeloid Leukemia (CML)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.